Spero Therap

Q2 FY2026 EarningsQ2 FY2026 EPS beat consensus, reporting a net loss per share of -$0.16 vs. -$0.17 expected. Total revenue was $0, in line with expectations following the full recognition of deferred collaboration revenue in prior periods. The quarter was highlighted by the FDA approval of Utebzi™ and a transformative $105M non-dilutive financing, extending the cash runway into H2 2029. Management’s pivot toward the SP001 immunology program remains the primary strategic focus following the Utebzi approval.